US$ 22.32
mechanism of action of glp 1 receptor agonist GLP-1 Agonists as Treatments for Type 2 Diabetes Mechanism of action of GLP-1
Description
Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, et al

First, make sure you revisit your drug plan every year

Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC

doi: 10.1210/jcem.80.3.7883856 99 KiefferTJMcIntoshCHPedersonRA

The PLGA delivery approach was applied in the design of a polymer microsphere formulation of exenatide in collaboration between Eli Lilly, Amylin and Alkermes [96]

Side Effects Comparison# Retatrutide Side Effects# Phase 2 trial data revealed: Gastrointestinal : Nausea (24-46%), diarrhea (16-26%), vomiting (9-20%), constipation (6-16%) Heart rate : Small mean increase (2-4 bpm) potentially related to glucagon receptor activation Injection site reactions : Mild and transient Hepatic : Transient elevations in liver enzymes observed Discontinuation rate : 6-10% due to adverse events in Phase 2 The glucagon receptor component introduces a unique side effect profile compared to GLP-1-only or GIP/GLP-1 dual agonists
